Innovation at the Intersection of Clinical Trials and Real-World Data Science to Advance Patient Care
Open Access
- 1 September 2018
- journal article
- review article
- Published by Wiley in Clinical and Translational Science
- Vol. 11 (5), 450-460
- https://doi.org/10.1111/cts.12559
Abstract
While efficacy and safety data collected from randomized clinical trials are the evidentiary standard for determining market authorization, this alone may no longer be sufficient to address the needs of key stakeholders (regulators, providers, and payers) and guarantee long-term success of pharmaceutical products. There is a heightened interest from stakeholders on understanding the use of real-world evidence (RWE) to substantiate benefit-risk assessment and support the value of a new drug. This review provides an overview of real-world data (RWD) and related advances in the regulatory framework, and discusses their impact on clinical research and development. A framework for linking drug development decisions with the value proposition of the drug, utilizing pharmacokinetic-pharmacodynamic-pharmacoeconomic models, is introduced. The summary presented here is based on the presentations and discussion at the symposium entitled Innovation at the Intersection of Clinical Trials and Real-World Data to Advance Patient Care at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2017 Annual Meeting.This publication has 50 references indexed in Scilit:
- Identification and Assessment of Adherence-Enhancing Interventions in Studies Assessing Medication Adherence Through Electronically Compiled Drug Dosing Histories: A Systematic Literature Review and Meta-AnalysisDrugs, 2013
- Financial Aspects and the Future of the Pharmaceutical Industry in the United States of AmericaMateria Socio-Medica, 2013
- Mechanism-Based Approach to the Economic Evaluation of PharmaceuticalsPharmacoEconomics, 2012
- History of evidence-based medicineIndian Journal of Urology, 2011
- Sharing Health Data for Better Outcomes on PatientsLikeMeJournal of Medical Internet Research, 2010
- The New Sentinel Network — Improving the Evidence of Medical-Product SafetyThe New England Journal of Medicine, 2009
- Contribution of economic evaluation to decision making in early phases of product development: A methodological and empirical reviewInternational Journal of Technology Assessment in Health Care, 2008
- External validity of randomised controlled trials: “To whom do the results of this trial apply?”The Lancet, 2005
- Role of Pharmacoeconomic Analysis in R&D Decision MakingPharmacoEconomics, 2005
- Economic Evaluations During Early (Phase II) Drug DevelopmentPharmacoEconomics, 2001